← Back to patent-cliff list
Keverprazan Hydrochloride
Tier C — Watch / tradeKeverprazan Hydrochloride
-
Originator
2023
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：H+/K+ ATPase
Indications (approved)：Helicobacter pylori infection, Duodenal ulcer, Peptic oesophagitis
Regional status
US
No progress
2021-06-24
EU
-
China
Approved
2023-02-14
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Keverprazan Hydrochloride?
Approved indications include: Helicobacter pylori infection, Duodenal ulcer, Peptic oesophagitis.
When does the Keverprazan Hydrochloride patent expire?
No public expiry year is available for Keverprazan Hydrochloride yet; this page updates once verified.
How do I get a quote for Keverprazan Hydrochloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27